Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

United States — Food and Drug Administration & Sanofi

11 shared events · Importance 3 · Last updated Aug 07, 2026

Importance
3
Shared Events
11
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
95
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration granted priority review to Sanofi's venglustat, indicating its potential to address an unmet medical need for type 3 Gaucher disease.
Sanofi: Sanofi has received priority review for its drug venglustat, which could significantly expand its portfolio in lysosomal storage diseases and provide a new revenue stream if approved.
May 28, 2026 · 6 articles
63
Regulatory
United States — Food and Drug Administration: The FDA granted approval for mFLUSIVA, marking a regulatory milestone and demonstrating its role in vaccine oversight despite internal controversies.
Sanofi: Sanofi's high-dose flu vaccine served as a comparator in trials; the new mRNA vaccine may compete with its products.
Aug 05, 2026 · 105 articles
59
Domestic
United States — Food and Drug Administration: Approved updated flu and COVID-19 vaccines, including Moderna's mFlusiva, enabling their availability for the fall season.
Sanofi: Partners with Novavax on the non-mRNA COVID-19 vaccine, gaining from potential increased demand.
Sep 02, 2026 · 20 articles
57
Business
United States — Food and Drug Administration: The US FDA provides supportive regulatory frameworks that facilitate product approvals and market growth in North America.
Sanofi: Sanofi is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
52
Regulatory
United States — Food and Drug Administration: Regulatory body that approved Lipfendra, enabling market entry.
Sanofi: Co-marketer of Praluent; faces similar competitive pressure.
Jul 16, 2026 · 93 articles
28
Regulatory
United States — Food and Drug Administration: The FDA's regulatory decisions are the subject of some of Kalshi's new contracts.
Sanofi: Sanofi is one of the companies whose drug approvals are being bet on, but is not directly involved.
Jul 16, 2026 · 7 articles
23
Business
United States — Food and Drug Administration: Reportedly rejected ITM-11's application over third-party manufacturing issues and approved Telix's Pixclara and Curium's Bexlutry; its approvals gate up to $250 million in milestone payments.
Sanofi: Named among recent radiopharmaceutical acquirers, underscoring competitive pressure in the sector that motivates Telix's vertical integration.
Sep 21, 2026 · 6 articles
12
Business
United States — Food and Drug Administration: Granted Fast Track and Breakthrough Therapy designations to lacutamab, facilitating its development and review.
Sanofi: Mentioned as a collaborator with Innate, not directly involved in this partnership.
Aug 10, 2026 · 10 articles
0
Business
Feb 24, 2026 · 8 articles
0
Business
Sanofi: Sanofi, in collaboration with Regeneron Pharmaceuticals, developed Dupixent and received International — European Commission approval for its use in treating chronic spontaneous urticaria in young children, which is expected to boost its market position and revenue.
Apr 13, 2026 · 8 articles
0
Regulatory
May 15, 2026 · 17 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States — Food and Drug Administration and Sanofi interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.